Linda Stocum, Associate Editor

A survey from the American Academy of Dermatology found that younger generations lack skin cancer knowledge.

Deucravacitinib meets primary end points for treating moderate to severe psoriasis.

The FDA has set a Prescription Drug User Fee Act (PDUFA) date for bimekizumab (UCB) for the treatment of psoriasis.